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ABSTRACT  
 
Background: We aimed to investigate the potential of standard hematologic and 
serum biochemical parameters to provide an independent and substantial 
contribution to the prediction of survival in patients with newly diagnosed brain 
metastases (BM).  
 
Methods: Hemoglobin, white blood cell count (WBC), platelet count, serum albumin, 
creatinine, lactate dehydrogenase (LDH), and C-reactive protein (CRP) were 
assessed at diagnosis of BM in a discovery cohort of 1200 cancer. A multivariable 
Cox regression model was used to derive the LabBM Score. The LabBM Score score 
was externally validated in an independent cohort consisting of 366 patients. 
 
Results: Hemoglobin below lower limit of normal (<LLN; HR 1.28; p=0.001), platelet 
count <LLN (HR 1.36; p=0.013), albumin <LLN (HR 1.19; p=0.038), LDH above 
upper limit of normal (>ULN; HR 1.51; p<0.001) and CRP >ULN (HR 1.52; p<0.001) 
were associated with survival in a multivariable Cox regression model and were 
included in the calculation of the LabBM score. Multivariable analysis including the 
LabBM Score and GPA class revealed an independent and significant association of 
the LabBM Score with OS (HR 1.42; 95% CI 1.29-1.57; p<0.001). The strong and 
independent association of LabBM score (HR 1.93; 95% CI 1.54-2.42) with OS 
prognosis was confirmed in the validation cohort.   
 
Conclusion: Standard clinical blood parameters, combined in the easy-to-calculate 
LabBM Score, provide strong and independent prognostic information in patients with 
BM. The LabBM Score is an objective, inexpensive and reproducible tool to plan 
N-O-D-16-00595R2 
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clinical management strategies in BM patients and to improve patient selection and 
stratification for clinical trials. 
 
Summary of importance: We introduce the easy-to-calculate LabBM Score, which 
is based on standard clinical blood parameters and provides strong and independent 
association with overall survival, irrespective of established prognostic factors in 
patients with newly diagnosed BM. The LabBM Score is an objective, inexpensive 
and reproducible tool to plan clinical management strategies in BM patients and to 
improve patient selection and stratification for clinical trials. 
 
 
Keywords: brain metastases, laboratory parameters, hemoglobin, albumin, CRP, 
lactate dehydrogenase  
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INTRODUCTION 
 
Brain metastases (BM) are a frequent complication occurring in up to 40% of cancer 
patients and are associated with high morbidity and mortality. Treatment modalities 
used for BM include neurosurgical resection, radiation therapy (radiosurgery and 
whole brain radiation therapy), chemotherapy, and increasingly also novel systemic 
drugs such monoclonal antibodies and tyrosine kinase inhibitors.1, 2 
 
So far, BM are in general incurable and median overall survival times are in the 
range of few months.3 However, survival times are highly variable with some patients 
succumbing to disease within few weeks and others achieving longer-term survival of 
several months or even years. Several BM-specific prognostic scores, such as the 
recursive partitioning assessment score (RPA), the graded prognostic assessment 
score (GPA) or the diagnosis-specific graded prognostic assessment score (DS-
GPA), have been established to facilitate estimation of patient outcomes for clinical 
decision-making and use in clinical trials.3 These scores are based on clinical 
characteristics such as patient age, Karnofsky performance status, status of the 
extracranial disease, number of BM and primary tumor type.3 Although the use of 
BM-specific prognostic scores provides valuable information for patient management 
and has been widely adopted, especially in the context of clinical trials, the prediction 
of survival times is inaccurate and needs improvement.4 Laboratory parameters 
routinely assessed in clinical practice have been shown to correlate with patient 
outcome in several diseases including cancer.5-8 Therefore, we hypothesized that 
standard hematologic and serum biochemical parameters could be valuable for 
prediction of survival in BM patients. We tested and confirmed our hypothesis in a 
large and well-defined discovery cohort of 1200 patients treated for newly diagnosed 
N-O-D-16-00595R2 
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BM at the Medical University of Vienna and an independent validation cohort of 366 
patients treated at the University Hospital Zurich. We provide an easy-to-calculate 
score based on standard clinical blood values that may be useful for survival 
prediction of BM patients in the clinical setting and in clinical trials (“LabBM Score”). 
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METHODS 
 
Patients 
The discovery cohort encompassed patients treated for newly diagnosed BM from 
solid extracranial cancers at the Medical University of Vienna between 1990 and 
2013. The independent validation cohort included patients treated for newly 
diagnosed BM from solid extracranial cancers at the University Hospital Zurich 
between 2004 and 2014. The discovery and the validation cohort were treated by 
independent multidisciplinary teams according to good clinical practice guidelines.  
 
Clinical data including information on the primary tumor, clinical course and survival 
times were retrieved by chart review. Graded prognostic assessment (GPA) was 
calculated according to previously published clinical characteristics.3, 9 The ethics 
committee of the Medical University of Vienna (Vote 078/2004) and Zurich (Vote 
KEK-ZH-Nr. 2015-0559) approved the study. 
 
Analyses of laboratory parameters 
Hemoglobin level (g/dl), platelet count (G/l), white blood cell count (WBC; G/l), serum 
albumin (g/l), serum creatinine (mg/dl), serum lactate dehyrogenase (LDH; U/l) and 
serum C reactive protein (CRP; mg/dl) were analyzed as part of the routine clinical 
assessment in the local department of laboratory medicine. We retrieved for this 
study only blood values that were analyzed within 14 days before or after the 
diagnosis of BM. Local standard cut off parameters were used for definition of lower 
limit of normal (LLN), within normal range (NR) and upper limit of normal (ULN; 
Supplemental table 1&2).   
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Statistical Analysis  
Overall survival (OS) was defined as time in months from diagnosis of BM to death or 
date of last follow-up. Primary tumor types with a frequency <5 were combined in the 
group “other primary tumor”. Laboratory parameters were classified into dummy 
variables (<LLN vs. NR vs. >ULN) according to the established local standard clinical 
cut off values (Supplemental Table 1&2). Then a univariable survival analysis was 
carried out for all parameters using Kaplan-Meier curves and two-sided log rank tests 
All laboratory parameters showing a statistically significant association (p<0.05) with 
survival prognosis in univariable analysis were included in the multivariate 
multivariable analysis.10 Dummy variables were defined as <LLN vs. not <LLN and 
>ULN vs. not >ULN as appropriate for the specific laboratory parameter. Laboratory 
parameters with statistically significant association with survival in the multivariable 
model were included in the LabBM score. The regression coefficient B was used to 
calculate the LabBM score. In order to obtain an easy-to-use score, the regression 
coefficient B was multiplied by 2 and rounded, resulting in values between 0.5 and 
1.0. Thus, 0 points were given for laboratory values within the normal range (NR) and 
depending on the parameter 0.5 to 1.0 points for values out of the normal range (LLN 
or ULN). The LabBM score was calculated for each patient in the discovery cohort. 
Based on the LabBM Score, 3 LabBM Score groups each containing one third of 
patients were defined in the discovery cohort, to give prognostic groups useful for 
clinical prognostic assessment and clinical trial planning. Patients with LabBM score 
0-1 were defined to belong to the low LabBM score group, 1.5-2 to the medium 
LabBM score group and 2.5-3.5 to the high LabBM score group. Therefore, the 
higher the LabBM score group the more pathological laboratory parameters were 
present in the individual patient. For further statistically analysis the LabBM score 
groups (low, medium, high) were used.  
N-O-D-16-00595R2 
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Association of the LabBM score with survival was again analyzed in a univariable 
analysis (log rank test), as well as in a multivariable analysis (Cox regression model) 
including the LabBM Score in addition to the established clinical prognosis score 
GPA. The Harrell’s C Index was calculated to investigate the prognostic accuracy of 
the LabBM Score.11 Then the LabBM Score was calculated for the patients in the 
independent validation cohort and analyzed for association with survival. Again, 
association of the LabBM Score group was investigated in a univariable analysis (log 
rank test) as well as in a multivariable analysis (Cox regression model) including the 
LabBM Score group and the GPA class (entered as categorical variable) as the most 
frequently applied prognostic assessment.9 To evaluate the added value of the 
LabBM Score groups Harrell’s C index was calculated for both LabBM Score and 
GPA class. A two tailed p-value of < 0.05 was considered significant. The study was 
conducted according to the TRIPOD statement guidelines.12  
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RESULTS 
Patients’ characteristics  
The discovery cohort consisted of 1200 patients and the validation cohort of 366 
patients, all with newly diagnosed BM from a histologically proven extracranial solid 
cancer. Table 1 lists further patients’ characteristics including distribution of the 
investigated laboratory parameters. Due to the retrospective nature of this project, 
not all blood parameters were available in all patients. A complete set of all 
investigated laboratory parameter was available in 811/1200 (67.6%) patients in the 
discovery and 177/366 (48.4%) patients of the validation cohort. Albumin and LDH 
were most commonly missing, while all other parameters were available in the vast 
majority of cases (Supplemental table 3). No difference in survival according to the 
availability of complete set of all investigated laboratory parameters was observed in 
the discovery cohort (7 months vs. 6 months; p=0.355; log rank test). In the validation 
cohort, patients with missing laboratory parameters had better survival than patients 
with a complete set of all investigated parameters (13 months vs. 7 months; p=0.015; 
log rank test).  
 
Prognostic impact of laboratory parameters in the discovery cohort  
Hemoglobin (p<0.001; log rank test), platelet count (p<0.001; log rank test), WBC 
(p=0.005; log rank test), albumin (p<0.001; log rank test), creatinine (p=0.018; log 
rank test), LDH (p<0.001; log rank test) and CRP (p<0.001; log rank test) showed an 
association with survival on univariable analysis (Table 2 Figure 1A-G).  
 
Development of the LabBM Score 
N-O-D-16-00595R2 
 11 
All laboratory parameters were entered in a Cox regression model for multivariable 
analysis and score development. Here, hemoglobin <LLN (HR 1.280; p=0.001), 
platelet count <LLN (HR 1.365; p=0.013), albumin <LLN (HR 1.191; p=0.038), LDH 
>ULN (HR 1.515; p<0.001) and CRP >ULN (HR 1.525; p<0.001) showed an 
association with survival and were included in the further development of the LabBM 
Score. Table 2 gives further details of the survival prognosis according to laboratory 
values in the discovery cohort. Next, the LabBM Score was formulated as indicated 
in the method section (Table 3). Based on the laboratory parameters, the LabBM 
score was calculated for 815/1200 (67.9%) patients in the discovery cohort, resulting 
in a score between 0 and 3.5 (Table 4). In 385/1200 (32.1%) patients calculation of 
the LabBM Score was not possible due to missing values (Supplemental Table 3). 
Importantly, Harrell’s C index of the LabBM Score model was 0.6386 compared to 
0.6465 if using all laboratory markers, showing that the information lost by the using 
the easy-to-use LabBM Score compared with the exact algorithm is minimal. In the 
discovery cohort survival of patients with missing LabBM Score did not differ from 
survival of patients with available LabBM Score (7 months vs. 7 months; p=0.266; log 
rank test).  
 
Median LabBM score was 1 (range 0-3.5). 268/815 (32.9%) patients belonged to 
LabBM Score group 0-1, 299/815 (36.7%) to LabBM Score group 1.5-2, and 248/815 
(30.4%) patients to LabBM Score group 2.5-3.5 (Table 4).  
 
The LabBM score group showed a significant association with OS from diagnosis of 
BM in the discovery cohort. Patients with low LabBM Score group (0-1 points) had a 
median OS of 11 months, patients in the medium LabBM Score group (1.5-2 points) 
of 7 months and patients in high LabBM Score group (2.5-3.5 points) of 3 months 
N-O-D-16-00595R2 
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(p<0.001; log rank test; Table 4; Figure 1H). Accordingly, the LabBM Score group 
showed a HR 1.579 (95% CI 1.435-1.738; p<0.001; Cox regression model).  
The GPA class presented with a statistical significant association with survival 
prognosis in the discovery cohort (HR 1.563; 95% CI 1.445-1.690; p<0.001; Cox 
regression model). To check whether the LabBM score contains information in 
addition to the GPA class, both variables were entered in a multivariable analysis. 
Here, the GPA class (HR 1.506; 95% CI 1.370-1.654; p<0.001: Cox regression 
model) as well as the LabBM Score group (HR 1.428; 95% CI 1.296-1.573; p<0.001; 
Cox regression model) showed an independent association with OS. The LabBM 
Score group presented with an independent statistical significant association with 
survival prognosis (HR 1.447; 95% CI 1.312- 1.597; p<0.001; Cox regression model) 
when entered with the individual data of the GPA i.e. age (HR 0.833; 95% CI 0.692- 
1.002; p=0.053; Cox regression model), Karnofsky performance status (HR 0.404; 
95% CI 0.326- 0.500; p<0.001; Cox regression model), number of BM (HR 0.623; 
95% CI 0.518- 0.749; p<0.001; Cox regression model) and presence of extracranial 
metastases (HR 0.812; 95% CI 0.694- 0.951; p=0.010; Cox regression model). To 
address the added value of the LabBM Score compared to the existing and 
established GPA score Harrell’s C index was calculated for both scores. Here, the 
GPA class showed a Harrell’s C index of 0.619, indicating a gain of 24% in 
prognostic accuracy compared to a null model with Harrell’s C index of 0.5.   and 
tThe LabBM score group resulted in a Harrell’s C index of 0.6386 and therefore the 
prognostic accuracy increased by 28% compared to the null model and by 4% 
compared to the model including only the GPA. Importantly, a combination score 
defined as the sum of GPA class and LabBM score showed a Harrell’s C index of 
0.680 and thereby an increase of prognostic accuracy by 36.1% compared to the null 
model, and by 12.1% compared to GPA only. (Supplemental table 5).  
Formatiert: Schriftart: Arial, 12 Pt., Englisch
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, showing that both scores show an association with survival prediction and that the 
LabBM Score indeed increased predictive accuracy in comparison with GPA.  
 
As the primary tumor type and applied BM therapy are additional important 
prognostic parameters, a multivariable analysis including the LabBM Score group, 
the GPA class, the primary tumor type and the applied therapy was calculated. As 
expected, the GPA class (p<0.001), the primary tumor type (p<0.001) as well as the 
applied therapy (p<0.001) showed associations with OS. In addition, also the LabBM 
Score group was significantly and independently associated with (HR 1.490; 95% 
1.249-1.645; p<0.001; Cox regression model) OS.  
 
Validation of the LabBM score  
External validation was performed in an independent validation cohort, consisting of 
patients treated at the University Hospital Zurich. Calculation of the LabBM Score 
was possible in 199/366 (54.4%) patients, while 167/366 (45.6%) patients were 
excluded from the analysis due to missing laboratory parameters. Survival prognosis 
in patients with available laboratory parameters for LabBM Score calculation was 
inferior to patients with missing LabBM Score (7 months vs. 13 months; p=0.010; log 
rank test). The GPA class was statistically significantly associated with survival 
prognosis in the validation cohort (HR 1.477; 95% CI 1.228-1.777; p<0.001; Cox 
regression model).  
 
Here, the LabBM Score groups confirmed the association with survival on univariable 
analysis. In the validation cohort, patients with low LabBM Score group (0-1 points) 
had a median OS of 10 months, patients in the medium LabBM Score group (1.5-2 
points) of 6 months and patients in the high LabBM Score group (2.5-3.5 points) of 1 
N-O-D-16-00595R2 
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months (p<0.001; log rank test, Table 4; Figure 1I). In line with the results from the 
discovery cohort, the LabBM Score group had a HR of 1.985 (95% CI 1.588-2.483; 
p<0.001; Cox regression model). Again, the independent association of the LabBM 
Score group (HR 1.932; 95% CI 1.542-2.420; p<0.001; Cox regression model) was 
retained at the multivariable analysis including the GPA class (HR 1.249; 95% CI 
0.978-1.595; p=0.075; Cox regression model).  
 
N-O-D-16-00595R2 
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DISCUSSION  
 
BM are an increasing challenge in general oncology and their prevalence is likely to 
increase. The prognosis of BM is highly variable. Here we report that standard 
laboratory blood parameters, combined in the LabBM Score, have a robust and 
independent prognostic value in patients with newly diagnosed BM. We identified low 
hemoglobin levels, low platelet counts, low albumin levels, high LDH levels and high 
CRP as adverse prognostic factors. Importantly, all the parameters are routinely 
tested in cancer patients and display as surrogate parameters important information 
on the bone marrow reserve, liver function, tumor cell turnover and infection. Several 
of these parameters have previously been reported as prognostically relevant in 
patients with advanced cancer and also non-malignant disorders.5, 7, 8, 13-16 The 
causes of laboratory anomalies may be manifold in cancer patients and may include 
previous applied therapies, paraneoplastic factors, effects of chronic disease, 
bleedings, malnutrition, toxicities of prior or concurrent therapies and others. Low 
hemoglobin and platelet counts may be surrogate parameters of impaired bone 
marrow reserve, low albumin levels may indicate malnutrition, and high LDH and 
CRP levels may be associated with high tumor load or underlying infections.15, 17 We 
did not intend to analyze the specific cause of abnormal blood values in individual 
cases, but view the LabBM score rather as a general indicator of disease activity and 
the patient´s biological constitution at the time of BM diagnosis. Of note, we 
investigated in our study only blood parameters measured at diagnosis of brain 
metastases and not during the disease course. Future research may evaluate the 
prognostic impact of blood values changes over time. 
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We consider the LabBM score as easy to apply in clinical practice, because it is 
based on routinely investigated parameters. In addition, the LabBM score is based 
on objectively measurable parameters, as blood values are in general assessed in 
specialized, certified and quality controlled laboratories and according to strict 
standard operating procedures. Other prognostic scores used for BM patients are 
based on more subjective criteria. The physician-assessed clinical performance 
score (e.g. KPS), which is prone to some inter-observer variability, is a core 
parameter of the GPA.18 Importantly, the prognostic value of the LabBM score was 
independent of the established prognostic GPA score as well as the histological 
tumor type and the applied therapy, thus indicating that consideration of blood values 
in addition to clinical parameters has added value for estimation of survival 
probabilities in BM patients. 
 
Despite the large investigated patient cohort of overall 1566 patients, the opportunity 
to investigate two separate cohorts and the availability of high-quality and detailed 
clinical data, our study has limitations. Due to the retrospective nature of this project, 
not all blood parameters were available in all patients. A complete set of all 
laboratory parameters of interest was available in 811/1200 (67.6%) patients in the 
discovery and 177/366 (48.4%) patients of the validation cohort. Albumin and LDH 
were missing in 28% and 17% of patients, respectively, while all other parameters 
were available in the vast majority of cases. Patients with missing values had a 
longer survival compared to patients with the full set of investigated laboratory 
parameters in the validation cohort. Although this finding might be a chance 
association, it might also be hypothesized that patients in a general good health 
status might be less likely to receive a full set of laboratory investigation compared to 
patients in an impaired health status. However, we decided to include all available 
N-O-D-16-00595R2 
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patients in the calculation and validation of the LabBM score to exclude any kind of 
inclusion bias. For optimal application of the LabBM score in the clinical setting 
standardized measurement of all five relevant parameters should be ensured. The 
two investigated cohorts were treated at two different centers and therefore resemble 
the standard real life cohorts at these particular centers. Although, the cohorts differ 
in some clinical characteristics the LabBM Score resulted in comparable results in 
both cohorts as an independent association with estimated survival was shown in 
both cohorts. Therefore, these data suggest that although our cohorts presented with 
some clinical differences, the LabBM Score is applicable to real life cohorts across 
centers.  Although the large sample size and the utilization of two cohort provide 
large statistical power and external validation of our results, the retrospective nature 
of our data need to be acknowledged as limitation and make prospective validation of 
the LabBM score desirable. 
 
In conclusion, the LabBM Score provides an objective, inexpensive and easily 
reproducible tool to estimate survival of patients with newly diagnosed BM. The 
LabBM score has an independent association with overall survival prognosis, 
irrespective of other established prognostic factors like the GPA class and adds 
substantial prognostic accuracy. In the future, the LabBM Score may help to plan 
clinical management strategies in BM patients or to improve patient selection and 
stratification for clinical trials. 
N-O-D-16-00595R2 
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Figure legend 
 
Figure 1: Overall survival according to laboratory parameter in the discovery cohort: 
A Hemoglobin; B Platelet count; C White blood cell count (WBC); D Albumin; E 
Creatinine; F Lactate dehydrogenase (LDH); G C reactive protein (CRP); Survival 
according to LabBM Score group in the discovery cohort (H) and the validation cohort 
(I); Abbreviations: LLN: Lower Limit of Normal; ULN: Upper Limit of Normal; NR: 
Normal range 
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Reviewer #1 
 
Berghoff and colleagues have addressed most of my comments appropriately. 
However, the main issue of this paper, whether the LabBM score is of (substantial) 
additional value in predicting survival, remains unclear to me. My question was if the 
LabBM score provided additional prognostic accuracy in addition to the established 
prognostic factors, for example calculated with Harell's C-index. Although the authors 
have calculated these C-indices 'for both scores', it is unclear to me how these 
models exactly look like. Which variables are included and what does this outcome 
tells us? Supplementary table 4 does not provide this answer. 
 
What I would like to see is results of: 
1)    A model with no variables (a null model) 
2)    A model with the clinical variables only 
3)    A model with the clinical variables and the LabBM score 
For example, if the prognostic accuracy increases from 0.5 (the null model) to 0.619 
(model 2, with clinical variables only), this represents a gain of 24% ((0.619-0.5)/0.5). 
If model 3 has a value of 0.6386, the gain is 28% ((0.6386-0.5)/0.5). This would 
mean that the additional prognostic value of the LabBM score is only 4%. 
 
If the analysis was indeed performed as stated above, I doubt if the LabBM score is 
indeed of substantial additional value. Although the LabBM is a strong and 
independent prognostic factor for survival, the increase in prognostic accuracy is only 
4% when compared to the clinical variables alone. 
 
Could the authors explain how they conducted the analysis and if they feel that the 
additional prognostic accuracy is indeed substantial?   
 
Our response: In order to address the reviewers question we added the following 
paragraph to the results section:  
 
“…To address the added value of the LabBM Score compared to the existing and 
established GPA score Harrell’s C index was calculated for both scores. Here, the 
GPA class showed a Harrell’s C index of 0.619, indicating a gain of 24% in 
prognostic accuracy compared to a null model with Harrell’s C index of 0.5.  The 
LabBM score group resulted in a Harrell’s C index of 0.6386 and therefore the 
prognostic accuracy increased by 28% compared to the null model and by 4% 
compared to the model including only the GPA. Importantly, a combination score 
defined as the sum of GPA class and LabBM score showed a Harrell’s C index of 
0.680 and thereby an increase of prognostic accuracy by 36.1% compared to the null 
model, and by 12.1% compared to GPA only. (Supplemental table 5)…” 
 
Therefore, the LabBM sore adds substantial prognostic accuracy as the addition of 
the LabBM score increases the prognostic accuracy from 24% for GPA alone to 
36.1% for the combination. We induced this information in the discussion section:  
 
“…The LabBM score has an independent association with overall survival prognosis, 
irrespective of other established prognostic factors like the GPA class and adds 
substantial prognostic accuracy…”   
 
Further we included supplemental table 5 including the results of all Harrell’s C 
models.  
 
Included variables Harrell’s C index Increase in prognostic 
accuracy compared to null 
model 
No variables 0.5 - 
GPA 0.619 24% 
LabBM score 0.639 28% 
GPA + LabBM score 0.683 36.6% 
 
 
Minor comment:  
1)    'Multivariate' is not everywhere changed into 'multivariable' (page 8 statistical 
analysis, supplementary table 4). 
 
Our response: As suggested by the reviewer ‘multivariate’ was changed to 
‘multivariable’ in the indicated sections.  
 
Reviewer #2: Critiques have been addressed 
Reviewer #3: Thank you for your review. Nothing to add. 
 
Our response: We thank reviewer #2 and reviewer #3 for the approval of our work.  
 
Sincerely, 
Anna Berghoff, Tim Holland-Letz and Matthias Preusser, on behalf of all co-authors  
SUPPLEMENTAL TABLES 
 
Supplemental Table 1: Standard values of laboratory parameters in the discovery 
cohort 
 
Parameter Lower limit of 
normal (LLN) 
Normal range 
(NR) 
Upper limit of 
normal (ULN) 
Hemoglobin (g/dl)    
male ≤13.4 13.5-18.0 ≥18.1 
female ≤11.9 12.0-16.0 ≥16.1 
Platelet count (G/l) ≤149 150-350 ≥351 
WBC (G/L) ≤3.9 4.0-10.0 ≥10.1 
Albumin (g/l) ≤34.9 ≥35 - 
Creatinine (mg/dl)    
male ≤0.6 0.7-1.2 ≥1.3 
female ≤0.4 0.5-0.9 ≥1.0 
Lactat 
dehydrogenase 
(LDH; U/L) 
- ≤249 ≥250 
C-reactive protein 
(CRP; mg/dl) 
- ≤0.50 ≥0.51 
 
 
Supplemental Table 2: Standard values of laboratory parameters in the validation 
 
Parameter Lower limit of 
normal (LLN) 
Normal range 
(NR) 
Upper limit of 
normal (ULN) 
Hemoglobin (g/dl)    
male ≤13.4 13.5-17.0 ≥17.1 
female ≤11.6 11.7-15.3 ≥15.4 
Platelet count (G/l) ≤141 142-400 ≥401 
WBC (G/L) ≤2.9 3.0-9.6 ≥9.7 
Albumin (g/l) ≤39 ≥40 - 
Creatinine (mg/dl)    
male ≤0.61 0.62-1.06 ≥1.07 
female ≤0.43 0.44-0.8 ≥0.9 
Lactat 
dehydrogenase 
(LDH; U/L) 
≤239 240-480 ≥481 
C-reactive protein 
(CRP; mg/dl) 
- ≤0.50 ≥0.51 
 
Supplemental Table 3: Available and missing laboratory parameters in the 
discovery and validation cohort  
 
Laboratory parameter Discovery cohort 
(n=1200) 
Validation cohort 
(m=366) 
 n % n % 
Hemoglobin 
Available  
Missing 
 
1200 
0 
 
100 
0 
 
366 
0 
 
100 
0 
Platelet count 
Available  
Missing 
 
1200 
0 
 
100 
0 
 
366 
0 
 
100 
0 
WBC 
Available  
Missing 
 
1200 
0 
 
100 
0 
 
363 
3 
 
99.2 
0.8 
Albumin 
Available  
Missing 
 
874 
326 
 
72.8 
27.2 
 
258 
108 
 
70.5 
29.5 
Creatinine 
Available  
Missing 
 
1164 
36 
 
97.0 
3.0 
 
329 
37 
 
89.9 
10.1 
LDH 
Available  
Missing 
 
1032 
168 
 
86.0 
14.0 
 
269 
97 
 
73.5 
26.5 
CRP 
Available  
Missing 
 
1112 
88 
 
92.7 
7.3 
 
367 
0 
 
100 
0 
 
Abbreviations: WBC: White blood cell count; LDH: lactate dehydrogenase; CRP: C 
reactive protein 
 
 
Supplemental Table 4: Results of the multivariable analysis in the validation cohort 
 
 Multivariable analysis (Cox regression model) 
 HR 95% CI P-value 
LabBM Score Group     
Low (0-1 point) (categorical)   <0.001 
Medium (1.5-2 points) 0.441 0.363-0.534 <0.001 
High (2.5-3.5 points) 0.538 0.448-0.646 <0.001 
GPA Class     
Class I (categorical)   <0.001 
Class II 0.365 0.264-0.505 <0.001 
Class III 0.415 0.312-0.551 <0.001 
Class IV 0.685 0.560-0.838 <0.001 
Primary tumor type     
Lung cancer (categorical)    
Breast cancer 1.257 0.872-1.812 0.221 
Melanoma 1.180 0.810-1.718 0.389 
Renal cell carcinoma 1.771 1.182-2.655 0.006 
Colorectal cancer 0.888 0.583-1.352 0.579 
Cancer of unknown primary 1.411 0.925-2.152 0.110 
Others 1.928 1.009-3.686 0.047 
Treatment   <0.001 
Stereotactic Surgery 
(categorical) 
   
Chemotherapy 0.233 0.136-0.399 <0.001 
Surgery 0.199 0.071-0.556 0.002 
Whole brain radiation 
therapy 
0.252 0.148-0.431 <0.001 
Best supportive care 0.330 0.192-0.570 <0.001 
 
Supplemental Table 5: Results of all Harrell’s C models 
 
Included variables Harrell’s C index Increase in prognostic 
accuracy compared to null 
model 
No variables 0.5 - 
GPA 0.619 24% 
LabBM score 0.639 28% 
GPA + LabBM score 0.680 36.1% 
 
